Pompe Disease: A Patient Guide

Pompe disease, also known as Glycogen Storage Disease Type II, is a rare genetic condition that fundamentally changes how the body handles energy. In a healthy body, an enzyme called acid alpha-glucosidase (GAA) acts like a pair of cellular scissors, breaking down a complex sugar called glycogen into glucose that the body can use for fuel. In people with Pompe disease, this enzyme is either missing or severely deficient. Without it, glycogen cannot be broken down and instead becomes trapped inside the lysosomes—the recycling centers of the cells. Over time, this trapped glycogen builds up and causes the lysosomes to enlarge and eventually leak, leading to progressive damage in the muscles used for movement, the diaphragm used for breathing, and, in some cases, the heart ^[1][2].

The way the disease behaves depends largely on how much working enzyme a person has. Doctors broadly categorize the disease into two main types on a clinical spectrum: Classic Infantile-Onset Pompe Disease (IOPD) and Late-Onset Pompe Disease (LOPD), though nonclassic infantile presentations also exist.

In the classic infantile form, symptoms usually appear within the first few months of life and are characterized by profound muscle weakness and a severely enlarged heart. Because this form progresses very quickly, early detection through newborn screening is a critical turning point. Identifying the disease in the first days of life allows for the urgent start of treatment, which can be lifesaving by protecting the heart from irreversible damage ^[3][4].

Late-onset Pompe disease can appear at any time after the first year of life, from early childhood through late adulthood. It follows a more variable and typically slower course than the infantile form, primarily affecting the muscles of the hips, spine, and shoulders. While LOPD generally lacks the severe cardiomyopathy of classic IOPD, mild or atypical cardiac involvement can sometimes occur. One of the most important aspects of LOPD is its effect on the respiratory system; the diaphragm may weaken even before a person notices significant trouble walking. Because of this, proactive and regular tracking of lung function is a cornerstone of long-term care. This monitoring ensures that any decline in breathing or muscle strength is caught early, allowing the medical team to adjust support as needed ^[5][6].

The standard of care for Pompe disease is Enzyme Replacement Therapy (ERT), a treatment that provides a supplemental version of the missing GAA enzyme through regular intravenous infusions. While ERT can stabilize or slow the decline of the disease, and improves survival remarkably in infants, it is not a cure and may not reliably reverse established damage. Furthermore, living with Pompe disease requires a multidisciplinary care team. This group of specialists—including neuromuscular specialists, pulmonologists, cardiologists, and physical therapists—works together to manage the many ways the condition can affect the body. By combining modern medicine with consistent monitoring and supportive therapies, patients and families can navigate the challenges of the diagnosis with a focused, proactive plan for the future ^[7][8].